Company intelligence / Profile preview
Feldan Therapeutics
Quebec City, Quebec, Canadafeldan.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Feldan's lead product FLD-103 for Basal Cell Carcinoma is currently in Phase 1/2a clinical trials. The company is also advancing a pulmonary program to address respiratory diseases.
- Therapeutic areas
- OncologyPulmonologyDermatology
- Modalities
- Peptide-based delivery technologyAntisense Oligonucleotides (ASOs)PMO (Phosphorodiamidate morpholino oligomers) RNA technologiesCell therapyNatural Killer Cell Therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ElasmogenZynext Ventures (Zydus Lifesciences)
Beyond the preview
Go deeper on Feldan Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Feldan Therapeutics.